Cambrex, a global contract development and manufacturing organization (CDMO), is nearing the completion of a 5-year, $100-million-dollar investment strategy, one year ahead of schedule. The project, which adds more than 150,000 square-feet of capacity and capability expansions across 70% of its North American and European drug development and manufacturing network, will be completed by the end of 2024. The investments span all scales of clinical and commercial drug substance manufacturing and include advanced technologies to solve for challenges related to complex molecules.

In North America, the 5-year investment strategy included capacity expansions in Charles City, Iowa and High Point, North Carolina, adding clinical and commercial manufacturing suites for small-volume, large-volume and highly potent API manufacturing. Cambrex expanded its capabilities in Longmont, Colorado to support early development programs, co-locating analytical services in the same facility as drug substance and drug product development. Cambrex also added specialized technologies for continuous flow process development and complex synthetics in Waltham, Massachusetts.

In Europe, Cambrex expanded its research and development capabilities in Milan, Italy, with a new high-potency lab for API process and analytical development and commissioned a new stability storage facility in Liege, Belgium.

In 2024, Cambrex will complete the final phases of expansion in both North America and Europe, adding a new, modernized quality control laboratory in Charles City, Iowa and commissioning two new 6m³ scale production lines, representing a 50% increase in large-scale API manufacturing capacity, in Karlskoga, Sweden.

With these investments, Cambrex continues to be well-positioned to support its customers in developing and manufacturing innovative new therapies that improve human health.

Visit Cambrex or use the Request Information button below to connect with the company.